{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:58:50Z","timestamp":1791644330773,"version":"4.3.4"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The oncostatin M receptor (OSMR) has recently emerged as an adverse prognostic factor in acute myeloid leukemia (AML) and several non-hematological malignancies. In this perspective, we discuss how oncostatin M (OSM) and its receptor OSMR regulate tumor cells as well as mesenchymal and endothelial cells, which are key components of hematopoietic stem cell and tumor stem cell niches, and how these mechanisms could explain the poor prognosis associated with high expression of OSM and OSMR in hematological and non-hematological malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2025.1636570","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:13Z","timestamp":1758087493000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Role and prognostic value of oncostatin M and its receptor OSMR in acute myeloid leukemia, myeloproliferative neoplasms and non-hematological malignancies"],"prefix":"10.3389","volume":"15","author":[{"given":"Jean-Pierre","family":"L\u00e9vesque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid G.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.51.32635","article-title":"Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation","volume":"271","author":"Mosley","year":"1996","journal-title":"J Biol Chem"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.1.165","article-title":"Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice","volume":"90","author":"Ichihara","year":"1997","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40568","article-title":"Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice","volume":"120","author":"Walker","year":"2010","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2015.07.006","article-title":"Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology","volume":"26","author":"Hermanns","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01413-z","article-title":"Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization","volume":"36","author":"Bisht","year":"2022","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11914-023-00837-z","article-title":"Oncostatin M: Dual regulator of the skeletal and hematopoietic systems","volume":"22","author":"Sims","year":"2024","journal-title":"Curr Osteoporos Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01165","article-title":"an underestimated player in the central nervous system","volume":"10","author":"Houben","year":"2019","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41467-018-03876-8","article-title":"Induction of muscle stem cell quiescence by the secreted niche factor oncostatin M","volume":"9","author":"Sampath","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155972","article-title":"Exogenous oncostatin M induces cardiac dysfunction, musculoskeletal atrophy, and fibrosis","volume":"159","author":"Jengelley","year":"2022","journal-title":"Cytokine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.08.013","article-title":"Oncostatin M is a major mediator of cardiomyocyte dedifferentiation and remodeling","volume":"9","author":"Kubin","year":"2011","journal-title":"Cell Stem Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8188","article-title":"Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma","volume":"14","author":"Headland","year":"2022","journal-title":"Sci Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.12.028","article-title":"Hepatic oncostatin M receptor \u03b2 regulates obesity-induced steatosis and insulin resistance","volume":"186","author":"Luo","year":"2016","journal-title":"Am J Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cells9010028","article-title":"Oncostatin M, a profibrogenic mediator overexpressed in non-alcoholic fatty liver disease, stimulates migration of hepatic myofibroblasts","volume":"9","author":"Foglia","year":"2020","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4307","article-title":"Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease","volume":"23","author":"West","year":"2017","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.739110","article-title":"Loss of oncostatin M signaling in adipocytes induces insulin resistance and adipose tissue inflammation in vivo","volume":"291","author":"Elks","year":"2016","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4615","article-title":"Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation","volume":"178","author":"Boniface","year":"2007","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.stem.2019.01.011","article-title":"A subset of TREM2+ dermal macrophages secretes oncostatin M to maintain hair follicle stem cell quiescence and inhibit hair growth","volume":"24","author":"Wang","year":"2019","journal-title":"Cell Stem Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030508","article-title":"Association between oncostatin M expression and inflammatory phenotype in experimental arthritis models and osteoarthritis patients","volume":"10","author":"Garcia","year":"2021","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M607005200","article-title":"Molecular and functional characterization of a soluble form of oncostatin M\/interleukin-31 shared receptor","volume":"281","author":"Diveu","year":"2006","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027244","article-title":"Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes","volume":"145","author":"Reville","year":"2025","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0367","article-title":"Targeted disruption of oncostatin M receptor results in altered hematopoiesis","volume":"102","author":"Tanaka","year":"2003","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1532\/ijh97.06090","article-title":"Oncostatin M maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow","volume":"84","author":"Minehata","year":"2006","journal-title":"Int J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116209","article-title":"Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis","volume":"9","author":"Sato","year":"2014","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci180981","article-title":"Human oncostatin M deficiency underlies an inherited severe bone marrow failure syndrome","volume":"135","author":"Garrigue","year":"2025","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain hematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2969","article-title":"Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self-renewal and chemoresistance","volume":"18","author":"Winkler","year":"2012","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.stem.2018.07.003","article-title":"Distinct bone marrow sources of pleiotrophin control hematopoietic stem cell maintenance and regeneration","volume":"23","author":"Himburg","year":"2018","journal-title":"Cell Stem Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nature17624","article-title":"Distinct bone marrow blood vessels differentially regulate hematopoiesis","volume":"532","author":"Itkin","year":"2016","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08352-6","article-title":"Bone marrow niches orchestrate stem-cell hierarchy and immune tolerance","volume":"638","author":"Furuhashi","year":"2025","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1038\/s41467-020-15817-5","article-title":"Endothelial E-selectin inhibition improves acute myeloid leukemia therapy by disrupting vascular niche-mediated chemoresistance","volume":"11","author":"Barbier","year":"2020","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B32","volume-title":"GEPIA Gene Expression Profiling and Interactive Analysis","author":"Tang","year":"2025"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.11.3820","article-title":"Divergent inducible expression of P-selectin and E-selectin in mice and primates","volume":"94","author":"Yao","year":"1999","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1096\/fj.11-193078","article-title":"Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms","volume":"26","author":"Hoermann","year":"2012","journal-title":"FASEB J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.72","article-title":"Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3+-mediated leukemic phenotype","volume":"30","author":"M\u00fcller","year":"2016","journal-title":"Leukemia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1097-2765(00)00067-8","article-title":"Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL\/JAK2","volume":"6","author":"Schwaller","year":"2000","journal-title":"Mol Cell"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027455","article-title":"Defective neutrophil clearance in JAK2V617F myeloproliferative neoplasms drives myelofibrosis via immune checkpoint CD24","volume":"146","author":"Khatib-Massalha","year":"2025","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90167.x","article-title":"Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis","volume":"65","author":"Koskela","year":"2000","journal-title":"Eur J Hematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-10-1712","article-title":"Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells","volume":"70","author":"Krishnamurthy","year":"2010","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-018-0426-4","article-title":"Cancer stem cells as key drivers of tumor progression","volume":"25","author":"Ayob","year":"2018","journal-title":"J BioMed Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-017-0595-x","article-title":"Cancer stem cell niche models and contribution by mesenchymal stroma\/stem cells","volume":"16","author":"Melzer","year":"2017","journal-title":"Mol Cancer"},{"key":"B42","volume-title":"The Human Protein Atlas","author":"Uhl\u00e9n","year":"2025"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2015.01.001","article-title":"Oncostatin-M differentially regulates mesenchymal and proneural signature genes in gliomas via STAT3 signaling","volume":"17","author":"Natesh","year":"2015","journal-title":"Neoplasia"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1038\/s41467-020-17885-z","article-title":"OSMR controls glioma stem cell respiration and confers resistance of glioblastoma to ionizing radiation","volume":"11","author":"Sharanek","year":"2020","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-22-0715","article-title":"Oncostatin-M and OSM-receptor feed-forward activation of MAPK induces separable stem-like and mesenchymal programs","volume":"21","author":"Polak","year":"2023","journal-title":"Mol Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-019-00934-y","article-title":"Oncostatin M receptor, positively regulated by SP1, promotes gastric cancer growth and metastasis upon treatment with Oncostatin M","volume":"22","author":"Yu","year":"2019","journal-title":"Gastric Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"7336","DOI":"10.1038\/s41467-021-27607-8","article-title":"Heterocellular OSM-OSMR signaling reprograms fibroblasts to promote pancreatic cancer growth and metastasis","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6665452","article-title":"OSM may serve as a biomarker of poor prognosis in clear cell renal cell carcinoma and promote tumor cell invasion and migration","volume":"2023","author":"Wei","year":"2023","journal-title":"Int J Genomics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-21-0345","article-title":"Endothelial reprogramming stimulated by oncostatin M promotes inflammation and tumorigenesis in VHL-deficient kidney tissue","volume":"81","author":"Nguyen-Tran","year":"2021","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa009","article-title":"Oncostatin M is a prognostic biomarker and inflammatory mediator for sepsis","volume":"221","author":"Gong","year":"2020","journal-title":"J Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020483","article-title":"Oncostatin M receptor type II knockout mitigates inflammation and improves survival from sepsis in mice","volume":"11","author":"Salim","year":"2023","journal-title":"Biomedicines"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/aor.14619","article-title":"Oncostatin M for characterizing the inflammatory burden and outcome of V-V ECMO in ARDS patients","volume":"47","author":"Setiadi","year":"2023","journal-title":"Artif Organs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac300","article-title":"Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis","volume":"62","author":"Denton","year":"2022","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1636570\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:38:14Z","timestamp":1758087494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1636570\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":54,"alternative-id":["10.3389\/fonc.2025.1636570"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1636570","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"article-number":"1636570"}}